| Name | Title | Contact Details |
|---|
Redmond and Greer Pharmacy Supply is a new and motivated corporation with many iconic brands in our portfolio. Our company began much like many independent pharmacies do, as a family business. Over a short time, the family business evolved into what is now one of the nation`s largest suppliers of niche market prescription medications and related products. Growing is at our heart and products are always changing use our expertise to make sure you`re on the forefront of these new products. Redmond and Greer Pharmacy Supply is a division of The Coney Consulting Group, LLC Our MISSION Our focus is providing value to our customers. We drive value to independent pharmacies by navigating the constantly changing business environment and keeping them in front of new products and profitable opportunities. Our VISION To be the preferred secondary wholesaler to the independent pharmacy market. Our VALUES Being pharmacist owned, we are highly focused on growing the business of the independent pharmacy. Our customers deserve the best, and to provide the best, we deliver all the tools a pharmacy needs to succeed – comprehensive product knowledge, access to pharmaceutical drugs at the best price, and a team that puts service and compliance above all else.
API Manufacturing Company
Ryan TrueHealth is a Wilton, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company is led by an experienced leadership team with world class scientific capabilities and proven expertise in DDR drug discovery, including the identification and development of the PARP inhibitor olaparib. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and The Francis Crick Institute, London. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers which will move into Phase 1 clinical studies in 2021. These include ATR inhibitor ART0380 for treating DDR defective tumours and the first-in-class Pol theta inhibitor ART4215 for mono therapy and combination treatments. In December 2020, Artios entered into a global three-year strategic research collaboration with Merck KGaA, Darmstadt, Germany to identify and develop precision oncology medicines targeting nucleases. Artios is backed by blue chip investors including: AbbVie Ventures, Andera Partners, Arix Bioscience plc, IP Group plc, Life Science Partners (LSP), M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in Cambridge, UK, with an office in New York City, USA.